利伐沙班用于75岁及以上急性内科疾病患者延长血栓预防
MARINER试验的预设亚组分析,比较出院后利伐沙班与安慰剂在≥75岁和<75岁急性内科疾病患者中的疗效与安全性。结果显示≥75岁患者主要事件率是<75岁的两倍,利伐沙班在两组中均数值上降低主要疗效终点,大出血发生率低且组间相似,≥75岁患者的获益/风险特征与总体人群一致。
要点
- ≥75岁急性内科疾病患者出院后症状性VTE及VTE相关死亡发生率是<75岁的两倍。
- 利伐沙班在≥75岁患者中数值上降低主要疗效终点(1.2% vs 1.6%,HR 0.73,95%CI 0.43-1.22)。
- 两个年龄组大出血发生率均低且相似,利伐沙班在≥75岁患者中的获益/风险与总体人群一致。
核心结论
- 利伐沙班在≥75岁急性内科疾病患者中的获益/风险特征与总体人群观察结果一致。
研究设计与样本
- MARINER试验为双盲随机对照试验,患者出院时随机接受利伐沙班(肌酐清除率≥50 ml/min者10 mg/日;≥30-<50 ml/min者7.5 mg/日)或安慰剂,疗程45天。
- 本分析按年龄≥75岁和<75岁进行预设亚组比较,采用包含治疗作为协变量的Cox比例风险模型。
主要发现
- ≥75岁患者主要事件率是<75岁患者的两倍。
关键数值与推荐
- 利伐沙班剂量:肌酐清除率≥50 ml/min者10 mg/日,≥30-<50 ml/min者7.5 mg/日,疗程45天。
- 主要疗效终点在≥75岁组HR 0.73(95%CI 0.43-1.22),<75岁组HR 0.78(95%CI 0.46-1.32)。
临床怎么用
- 对于≥75岁急性内科疾病患者,出院后延长血栓预防可考虑利伐沙班,但需评估出血风险。
- 利伐沙班在≥75岁患者中的获益/风险与总体人群一致,支持在该人群中使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although older patients are at increased risk for venous thromboembolism (VTE), thromboprophylaxis is underused because of bleeding concerns. The MARINER trial evaluated whether rivaroxaban reduced symptomatic postdischarge VTE in acutely ill medical patients. OBJECTIVES: We hypothesized that rivaroxaban would have a favorable benefit/risk profile in patients ≥75 years of age. METHODS: Patients were randomized in a double-blind manner at hospital discharge to rivaroxaban (10 mg/day for creatinine clearance ≥50 ml/min; 7.5 mg/day for ≥30-<50 ml/min) or placebo for 45 days. Using a Cox proportional hazard model including treatment as a covariate, we compared the risk of the primary efficacy outcome (symptomatic VTE plus VTE-related death in the intention-to-treat population) and safety outcome (International Society on Thrombosis and Haemostasis major bleeding in the safety population) in the prespecified subgroups of patients ≥ and <75 years of age. RESULTS: The primary event rate in patients ≥75 years of age was 2-fold higher than that in those <75 years. The incidence of the primary efficacy outcomes in both age groups was numerically lower with rivaroxaban than with placebo (≥75: 1.2% and 1.6%, HR 0.73, 95% CI 0.43-1.22; <75 0.6% and 0.8%, HR 0.78, 95% CI 0.46-1.32; interaction p-value for age group = .85). The incidence of major bleeding was low and similar in the two age and treatment groups (interaction p value for age group = .35). CONCLUSION: Symptomatic VTE and VTE-related death occur frequently in older patients with acute medical illness. The benefit/risk profile of rivaroxaban in patients ≥75 years of age appears consistent with that observed in the general population.
引用
- Ageno W, Lopes RD, Goldin M, et al. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021. PMID: 34314574. doi:10.1111/jth.15477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。